| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Issuance of restricted shares as compensation towards directors | 0 | 0 |
| Linkage difference on principal of loans from stockholders | 0 | 0 |
| Net loss | -15,760 | -11,589 |
| Depreciation and amortization | 28 | 19 |
| Stock-based compensation | 121 | 80 |
| Change in fair value of derivative liability | -3,269 | -3,269 |
| Amortization of debt discount and interest expense related to promissory notes | 5 | 5 |
| Amortization of original issue discount related to promissory note | 31 | - |
| Other current assets | 86 | 371 |
| Accounts payable | 717 | 1,652 |
| Other current liabilities | 272 | 157 |
| Loss on warrant repurchase | 99 | 95 |
| Net cash used in operating activities | -11,304 | -6,683 |
| Purchase of property and equipment | 76 | 9 |
| Net cash used in investing activities | -76 | -9 |
| Issuance of convertible promissory notes and bifurcated conversion feature through private placement transaction | 0 | - |
| Issuance of convertible promissory note, bifurcated conversion and redemption features and detachable warrants through private placement transaction | 0 | - |
| Issuance of notes and warrants through private placement transaction | 0 | 0 |
| Net proceeds from private placement transaction | 0 | 0 |
| Net proceeds from underwritten u.s. public offerings (note 3a) | 10,715 | 10,715 |
| Series a warrant repurchase | 166 | 160 |
| Net proceeds from promissory note | 3,000 | - |
| Net cash provided by financing activities | 13,549 | 10,555 |
| Effect of exchange rate changes on cash and cash equivalents, and restricted cash | 73 | 65 |
| Change in cash and cash equivalents, and restricted cash | 2,242 | 3,928 |
| Cash and cash equivalents at beginning of period | 5,627 | - |
| Cash and cash equivalents at end of period | 7,869 | - |
Glucotrack, Inc. (GCTK)
Glucotrack, Inc. (GCTK)